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Pax5 is an essential regulator of B cell identity and
function. Here, we used transgenesis and deletion
mapping to identify a potent enhancer in intron 5 of
thePax5 locus. This enhancer in combinationwith the
promoter region was sufficient to recapitulate the
B lymphoid expression of Pax5. The enhancer was
silencedbyDNAmethylation in embryonic stemcells,
but became activated in multipotent hematopoietic
progenitors. It contained functional binding sites
for the transcription factors PU.1, IRF4, IRF8, and
NF-kB, suggesting that these regulators contribute
to sequential enhancer activation in hematopoietic
progenitors and during B cell development. In
contrast, the promoter regionwas repressedbyPoly-
combgroupproteins innon-Bcells andwasactivated
only at the onset of pro-B cell development through
induction of chromatin remodeling by the transcrip-
tion factor EBF1. These experiments demonstrate
a stepwise activation of Pax5 in early lymphopoiesis
and provide mechanistic insights into the process of
B cell commitment.
INTRODUCTION
Hematopoietic stem cells (HSCs) develop into B cells by first
differentiating to lymphoid-primed multipotent progenitors
(LMPPs) and common lymphoid progenitors (CLPs). Entry of
the CLPs into the B cell lineage depends on the transcription
factors E2A, EBF1, and Pax5 (Cobaleda et al., 2007b; Nutt and
Kee, 2007). Pax5 controls the commitment of lymphoid progen-
itors to the B cell pathway by repressing B lineage-inappropriate
genes (Delogu et al., 2006) and by activating B cell-specific
genes (Schebesta et al., 2007). This reprogramming of gene
expression restricts the broad signaling capacity of uncom-
mitted progenitors to the B cell lineage, facilitates (pre-) B cell
receptor signaling, promotes B lymphocyte differentiation, and
regulates B cell adhesion and migration (Delogu et al., 2006;
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function, Pax5 is exclusively expressed in the B lymphoid lineage
from the committed pro-B cell to the mature B cell stage and is
subsequently repressed during terminal plasma cell differentia-
tion (Fuxa and Busslinger, 2007). Pax5 expression is continu-
ously required throughout B cell development, as indicated by
the fact that conditionalPax5 inactivation induces the conversion
of mature B cells into functional T cells via dedifferentiation to
uncommitted progenitors (Cobaleda et al., 2007a). These
studies identified Pax5 as a crucial guardian of B lymphocyte
identity and function. The human PAX5 gene was furthermore
implicated in B cell malignancies by specific chromosomal
translocations, which activate PAX5 as an oncogene in acute
lymphoblastic leukemias and non-Hodgkin lymphomas (Coba-
leda et al., 2007b). Moreover, conditional Pax5 loss in mature
B cells generates progenitor cell lymphomas in the mouse,
demonstrating that Pax5 can function as a tumor suppressor
or oncoprotein in the generation of different lymphoid malignan-
cies (Cobaleda et al., 2007a).
Despite the importance of Pax5 for B cell commitment,
function, and lymphomagenesis, little is yet known about
upstream regulators that control the initiation and subsequent
maintenance of Pax5 expression during B cell development.
Genetic evidence indicates that the transcription factors E2A
and EBF1 act upstream of Pax5 in adult B lymphopoiesis,
because Pax5 transcripts cannot be detected in lymphoid
progenitors lacking E2A or EBF1 (Bain et al., 1994; Lin and Gros-
schedl, 1995). EBF1 is thought to activate the Pax5 gene by
binding to a recognition sequence 1110 bp upstream of the tran-
scription start site of the distal Pax5 promoter (O’Riordan and
Grosschedl, 1999). This EBF1 recognition sequence was subse-
quently shown to overlap with a binding site for the transcription
factor STAT5 (Goetz et al., 2005; Hirokawa et al., 2003), leading
to the suggestion that both transcription factors cooperatively
activate the Pax5 gene by binding to this composite element
(Hirokawa et al., 2003). However, this putative regulatory
element has never been functionally analyzed within the context
of the Pax5 gene in B lymphocytes.
The 190-kb-long Pax5 gene is transcribed from two separate
promoters, which give rise to two distinct mRNAs by splicing
of alternative 50 exons (1A and 1B) onto the common coding
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B lymphocytes,Pax5 is also expressed at the midbrain-hindbrain
boundary (MHB) of midgestation embryos (Adams et al., 1992).
In this developing brain region, Pax5 is primarily transcribed
from its proximal promoter upstream of exon 1B, whereas both
the distal and proximal Pax5 promoters are active in B lympho-
cytes (Busslinger et al., 1996). By using transgenic analysis, we
have previously identified a 435 bp enhancer (located 5.6 kb
upstream of exon 1A), which is sufficient to drive reporter gene
expression in the developing MHB region (Pfeffer et al., 2000).
A 25 kb fragment of Pax5 50 sequences spanning from 15 kb
upstream of exon 1A to exon 2 was, however, unable to activate
reporter transgene expression in B lymphocytes, indicating that
the B cell-specific control region(s) must reside at a distant loca-
tion from the Pax5 promoters (Pfeffer et al., 2000).
Here we have used Pax5 bacterial artificial chromosomes
(BACs) for transgenesis and deletion mapping to identify a B
cell-specific enhancer in intron 5 of the Pax5 locus. This
enhancer together with the Pax5 promoter region was sufficient
to recapitulate the B lymphoid expression of Pax5 in transgenic
mice. The enhancer was regulated by the transcription factors
PU.1, IRF4, IRF8, and NF-kB and was activated already in multi-
potent hematopoietic and lymphoid progenitors. In contrast, the
promoter region was activated only at the onset of pro-B cell
development by EBF1-dependent chromatin remodeling. Our
experiments therefore provide molecular insights into the
transcription factor network governing the stepwise activation
of Pax5 during early lymphopoiesis.
RESULTS
BCell-Specific Expression ofPax5-GfpBACTransgenes
Because a 25 kb fragment from the Pax5 50 region failed to give
rise to B lymphoid expression in transgenic mice (Pfeffer et al.,
2000), we investigated whether all necessary regulatory
elements for correct B cell-specific expression were present
on two large bacterial artificial chromosomes (BACs) containing
sequences of the Pax5 locus from 110 kb (BAC1) or 18 kb
(BAC2) to intron 6 (Figure S1A available online). To monitor trans-
gene expression, we inserted a Gfp reporter gene in-frame into
Figure 1. Pax5-Gfp BAC Transgenes Recapitulate
the B Lymphoid Expression Pattern of Pax5
GFP expression was monitored by flow cytometric
analysis in hematopoietic cells of a Pax5-Gfp BAC2
transgenic mouse (green area) relative to a wild-type
control littermate (black line). Cell types of the bone
marrow and lymph nodes (mature B cells) were analyzed
and defined as described in Experimental Procedures.
A schematic diagram of the Pax5-Gfp BAC1 and BAC2
transgenes is shown in Figure S1 together with the GFP
expression of the BAC1 transgenic line.
Pax5 exon 2 and generated a transgenic line
for each of the two modified Pax5-Gfp BACs
(Figure S1A). Flow cytometric analysis revealed
that the BAC1 and BAC2 transgenic mice gave
rise to high GFP expression throughout B cell
development from pro-B to mature B cells
(Figure 1; Figure S1B). In contrast, GFP expression was not
detected in non-B cells of the bone marrow and in thymocytes
(Figure 1; Figure S1B). Both BAC transgenic lines also expressed
GFP in the midbrain-hindbrain boundary (MHB) region of
midgestation embryos (Figure S1B; data not shown), consistent
with the presence of the MHB-specific enhancer on both Pax5
BACs (Figure S1A). Hence, the two Pax5-Gfp BAC transgenes
specifically expressed GFP in the embryonic MHB region and
the B cell lineage, which constitute the two major Pax5 expres-
sion domains in the mouse.
We previously characterized the B lymphoid expression
pattern of the Pax5iGfp/iGfp mouse that carried an IRES-Gfp
reporter gene insertion in the 30 untranslated region of the Pax5
gene (Fuxa and Busslinger, 2007). The endogenous Pax5iGfp
allele was not expressed in multipotent progenitors (MPPs) of
the bone marrow and was subsequently induced only in a small
population of CLPs prior to its full activation in committed pro-B
cells (Fuxa and Busslinger, 2007). Similar to the Pax5iGfp/iGfp
mouse, no GFP expression could be detected in MPPs of
Pax5-Gfp BAC2 transgenic mice, and only a subpopulation
(19.8%) of CLPs started to express GFP in this transgenic line
(Figure 1). Importantly, GFP expression was repressed in termi-
nally differentiated plasma cells of BAC2 transgenic mice
(Figure 1) similar to the loss of GFP expression in plasma cells
of Pax5iGfp/iGfp mice (Fuxa and Busslinger, 2007). Hence, the
Pax5-Gfp BAC transgenes recapitulate the B cell-specific
expression pattern of the endogenous Pax5 gene and thus
contain all regulatory elements that are required for the initiation,
maintenance, and repression of Pax5 during the differentiation of
HSCs to plasma cells.
Identification of B Cell-Specific Regulatory Elements
in Intron 5 of Pax5
To localize B cell-specific regulatory elements, we generated
transgenic lines carrying specific deletions in the Pax5-Gfp
BACs (Figure 2A). The BAC1-D50 transgene still gave rise to
GFP expression in B cells, although it carried a deletion of
100 kb of 50 flanking sequences, leaving only 12 kb upstream
of the distalPax5 promoter (Figure 2A). These 12 kb were deleted
in BAC2-D14kb, which retained only 200 bp of minimal promoter
Immunity 30, 508–520, April 17, 2009 ª2009 Elsevier Inc. 509
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Figure 2. Mapping of Regulatory Elements in the Pax5 Locus by Deletion Analysis
(A) Schematic diagram of the BAC deletion constructs (left) and statistical evaluation of the GFP expression pattern of the corresponding transgenic lines (right).
Red dashed lines indicate the deletions introduced in BAC1 or BAC2. The respective transgenic lines were evaluated with regard to their GFP expression in
mature B cells, non-B cells of the bone marrow, and the embryonic MHB region. Mature B cells of the transgenic BAC1-D30 and BAC1-DIn5 lines expressed
GFP only at a very low level, which was scored as negative compared to the strong GFP expression of other transgenic lines. An asterisk (*) denotes variegated
GFP expression in the two lines carrying the BAC2-D14kb transgene, as shown in Figure S2. GFP was only weakly expressed in non-B cells (CD19B220) of the
bone marrow and/or thymocytes of the three ectopically expressing lines. n.a., not analyzed.
(B and C) Flow cytometric analysis of GFP expression in mature B cells of the indicated transgenic lines (B) and in different B cell types of a BAC1-DIn5 transgenic
line (C).
(D) GFP expression in the MHB region and neural tube (NT) of an E11.5 embryo carrying the BAC1-DIn5 transgene.
510 Immunity 30, 508–520, April 17, 2009 ª2009 Elsevier Inc.
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B Cell-Specific Regulation of Pax5sequences upstream of Pax5 exon 1A. Both BAC2-D14kb
transgenic lines still expressed GFP in B cells (Figure 2A), but
expression strongly variegated at different stages of B cell
development (Figure S2). These results therefore indicated that
critical B cell-specific regulatory elements must reside within
the Pax5 gene.
The BAC1-D30 transgenic line expressed GFP very weakly in
mature B cells because of the absence of Pax5 intragenic
sequences from exon 2 to intron 6 (Figures 2A and 2B). Deletion
of individual introns revealed strong GFP expression in mature B
cells of all BAC1 transgenic lines lacking intron 2, 3, 4, or 6 (Figures
2A and 2B). In contrast, deletion of intron 5 in the BAC1-DIn5
transgene led to minimal GFP expression in mature B cells despite
normal GFP expression in the MHB region of E11.5 embryos
(Figures 2A, 2C, and 2D). Low GFP expression was still detected
in pre-B and immature B cells of BAC1-DIn5 transgenic mice,
suggesting that the promoter region of Pax5 has a low intrinsic
activity in these cell types (Figure 2C). Together these data
demonstrate that the B cell-specific expression of Pax5 critically
depends on regulatory elements located within intron 5.
Mapping of DNase I Hypersensitive Sites
in the Pax5 Locus
To localize regulatory elements in the 34-kb-long intron 5, we
used in vitro cultured pro-B cells to systematically map DNase
I hypersensitive sites by indirect end-labeling of overlapping
restriction fragments. This analysis identified one hypersensitive
region (HSR) with four HS sites within a 9.3 kb ScaI fragment of
intron 5 (Figure 3A). Three strong HS sites (referred to as HS-A,
HS-B, and HS-C) and one weak site (HS-D) were detected in
cultured pro-B cells and mature B cells of the lymph node
(Figure 3A; Figure S3A). The same three HS sites were also found
at equivalent positions within PAX5 intron 5 in human Raji B cells
(Figure S4). All four HS sites were absent in CD19 non-B cells of
the bone marrow, whereas HS-C was still present in thymocytes
(Figures S3B and S3C). Hence, the hypersensitive region in
intron 5 of Pax5 consists of two B lymphoid sites (HS-A and
HS-B), one lymphocyte-specific site (HS-C), and a weak site
(HS-D). Surprisingly, these four HS sites show only a moderate
overall sequence conservation compared to other regions in
the Pax5 locus (Figure 3C).
Similar experiments identified eight HS sites in the promoter
region of Pax5 in pro-B and mature B cells (Figure 3B;
Figure S3D). HS-4 and HS-8 coincide with the 50 ends of exons
1A and 1B, respectively, whereas the other sites are located
upstream of exon 1A (HS-1 to HS-3) or in the intron separating
the two Pax5 promoters (HS-5 to HS-7). Seven HS sites (HS-1
to HS-7) were absent in T cells of the thymus and non-B cells
of the bone marrow, whereas HS-8 was ubiquitously present in
different cell types (Figures S3E and S3F). In summary, we
have identified 12 HS sites in the Pax5 promoter region and
intron 5, which probably contain the cis-regulatory elements
for B cell-specific Pax5 expression, because nine of these sites
are exclusively present in B lymphocytes.
Identification of Active Chromatin Domains
in the Pax5 Locus
We next mapped active histone modifications along the Pax5
locus by chromatin immunoprecipitation-coupled DNA microar-ray analysis (ChIP-chip) by using antibodies that recognize
acetylated lysine 9 (H3K9ac), dimethylated lysine 4 (H3K4me2),
or trimethylated lysine 4 (H3K4me3) on histone H3 (Figure 3C).
ChIP-chip analysis of Pax5+/+ pro-B cells revealed broad enrich-
ment of all three active histone marks at the promoter region of
Pax5 (Figure 3C). A similar histone-modification pattern was
also observed in Pax5/ pro-B cells, indicating that Pax5
does not control the generation of active chromatin at its own
locus (Figure S5). A second large domain of H3K9ac and
H3K4me2 modifications extended from intron 4 to intron 5
including the two HS-A and HS-B sites. This domain lacked
the H3K4me3 mark in agreement with the known histone-modi-
fication pattern H3K9ac+ H3K4me2+ H3K4me3 for active
enhancers (Schebesta et al., 2007). The chromatin profile of
the hypersensitive region in intron 5 thus predicts that these
sequences function as an enhancer in B cells.
The Hypersensitive Region in Intron 5 Functions
as a B Cell-Specific Enhancer of Pax5
We next investigated whether the HS clusters in the Pax5
promoter region and intron 5 were sufficient to direct B cell-
specific expression in transgenic mice (Figure 4; Figure S6A).
To this end, we generated the transgene PromGFP containing
the entire Pax5 promoter region from the MHB enhancer to
exon 2 fused to a Gfp reporter gene. PromGFP transgenic
mice failed to express GFP in pro-B and mature B cells, but
gave rise to low GFP expression in pre-B and immature B cells
(Figure 4A) similar to the BAC1-DIn5 transgene (Figure 2C). In
contrast, high GFP expression was observed in all B cell types
of a PromGFP-ABC transgenic line, in which the intronic HS sites
A, B, and C were inserted downstream of the Gfp gene
(Figure 4B). Notably, GFP expression was initiated in a small
subpopulation (12%) of CLPs and downregulated in terminally
differentiated plasma cells, but was not observed in MPPs
and non-B cells of the bone marrow (Figure 4B). Hence, the
PromGFP-ABC transgene recapitulated the expression pattern
of the Pax5-Gfp BAC2 transgene (Figure 1) and the endogenous
Pax5iGfp allele (Fuxa and Busslinger, 2007). We therefore
concluded that the three HS sites A, B, and C in intron 5 together
with the eight HS sites in the promoter region are sufficient to
direct B lineage- and developmental stage-specific expression
of Pax5.
Analysis of two additional PromGFP-ABC transgenic lines
revealed that GFP expression was high in a subset of B lympho-
cytes, but was variegated, because the number of GFP-express-
ing cells gradually increased from the pro-B to the mature B cell
stage (Figure S6C). We obtained the same result after further
inclusion of HS-D in transgene PromGFP-ABCD, as shown by
the fact that one transgenic line showed uniformly high GFP
expression in all B cells, whereas GFP expression was varie-
gated in two additional lines (Figure S7). Hence, the HS sites in
Pax5 intron 5 do not function as a locus control region (LCR),
which is defined as a regulatory element enabling chromosomal
position-independent gene expression by overriding the nega-
tive influence of heterochromatin at the transgene integration
site (Festenstein and Kioussis, 2000). An LCR element appears
to be absent also in the entirePax5-GfpBAC transgene, because
no clear correlation between GFP expression levels and trans-
gene copy numbers was observed for different BAC transgenic
Immunity 30, 508–520, April 17, 2009 ª2009 Elsevier Inc. 511
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elements in intron 5 function as a potent B cell-specific
enhancer, but lack LCR activity.
EBF1-Dependent Formation of Hypersensitive Sites
in the Pax5 Promoter Region
E2A (Tcfe2a) and EBF1 act genetically upstream of Pax5 in adult
B lymphopoiesis (Bain et al., 1994; Lin and Grosschedl, 1995),
but their precise role in activating the Pax5 locus is still unknown.
To this end, we generated E2A- and EBF1-deficient progenitor
cells by in vitro culturing of Tcfe2a/ or Ebf1/ MPPs on OP9
A
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Figure 3. Mapping of DNase I Hypersensi-
tive Sites and Active Chromatin in the Pax5
Locus
(A)Pax5 intron 5. Strategy (top): DNase I hypersen-
sitive sites (HS) were mapped by indirect end-
labeling within the 6.5 kb PstI and 9.3 kb ScaI
fragments by using the Southern blot probes E1
and E2, respectively. The approximate locations
of the four HS sites, constituting a hypersensitive
region (HSR), are shown relative to the positions
of reference restriction enzyme sites. HS mapping
(bottom): Nuclei of in vitro cultured wild-type pro-B
cells were treated with increasing DNase I concen-
tration, and the isolated DNA was digested with
PstI or ScaI prior to Southern blot analysis. The
positions of reference restriction sites shown to
the left were determined by including genomic
DNA, which was double digested with the indi-
cated restriction enzyme and PstI or ScaI, in the
Southern blot analysis.
(B) Pax5 promoter region. Strategy (top): The
12.3 kb BamHI fragment used for HS mapping is
shown together with the Southern blot probes P1
and P2, the positions of the reference restriction
enzyme sites, and the approximate locations of
the eight HS sites. HS mapping (bottom): Pro-B
cell nuclei were treated with increasing DNase I
concentration prior to DNA isolation, BamHI diges-
tion, and Southern blotting. The positions of
reference restriction sites were determined as
described in (A).
(C) Chromatin profiling. A DNA sequence conser-
vation track (top) is shown above a schematic
diagram of the mouse Pax5 locus indicating the
location of its exons, MHB-specific enhancer,
and HS sites. Chromatin mapping (bottom):
Pax5+/+ Rag2/ pro-B cells were used for
ChIP-chip analysis with H3K9ac, H3K4me2, and
H3K4me2 antibodies as described (Schebesta
et al., 2007). The logarithmic ratio (log2) of the
hybridization intensities between antibody-precip-
itated and input DNA (bound/input) is shown as
a bar for each oligonucleotide on the microarray.
The results are representative of two independent
ChIP-chip experiments.
feeder cells in the presence of IL-7,
SCF, and Flt3 ligand (Ikawa et al., 2004;
Kwon et al., 2008). Flow cytometric anal-
ysis identified the cultured Tcfe2a/ and
Ebf1/ cells as lymphoid progenitors
with the characteristic cell surface pheno-
type IL-7Ra+c-Kit+B220+CD43+BP1CD19 of uncommitted
pre-pro-B cells (Figure S9A). Immunoblot analysis revealed no
expression of E2A, EBF1, and Pax5 in Tcfe2a/ progenitors,
whereas Ebf1/ progenitors expressed E2A in the absence of
EBF1 and Pax5 (Figure S9B). We next investigated the presence
of HS sites in Tcfe2a/, Ebf1/, and controlPax5/ progenitor
cells (Figures 5A and 5B). Whereas all HS sites were present in
Pax5/ pro-B cells, seven HS sites (HS-1 to HS-7) were absent
from the Pax5 promoter region in both Tcfe2a/ and Ebf1/
progenitors (Figure 5A). Because E2A is expressed in Ebf1/
progenitors, we conclude that EBF1 (and not E2A) is required
512 Immunity 30, 508–520, April 17, 2009 ª2009 Elsevier Inc.
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tantly, all HS sites in the intronic enhancer of Pax5 were still
present in Tcfe2a/ and Ebf1/ progenitors (Figure 5B), indi-
cating that activation of the Pax5 enhancer does not depend
on E2A or EBF1.
We next used ChIP analysis to detect active (H3K9ac) or
repressive (H3K27me3) histone modifications at all Pax5 HS
sites in Tcfe2a/ and Ebf1/ progenitors as well as in control
Pax5/ and wild-type pro-B cells (Figure 5C; Figure S10). In
agreement with our ChIP-chip data (Figure 3C), all HS sites in
the Pax5 promoter and enhancer regions (except for HS-C)
carried active H3K9ac marks in Pax5/ and wild-type pro-B
cells, whereas the repressive H3K27me3 modification was
absent at all HS sites (Figure 5C; Figure S10). Similarly, the exis-
tence of HS-A and HS-B in Tcfe2a/ and Ebf1/ progenitors
A
B
Figure 4. The Hypersensitive Region in
Intron 5 Functions as a B Cell-Specific
Enhancer
(A) Basal activity of the Pax5 promoter region.
A DNA fragment containing the entire Pax5
promoter region from the MHB enhancer (at posi-
tion 6,074) to exon 2 (at position +13,368) was
fused in-frame in exon 2 to a Gfp reporter gene
to generate transgene PromGFP. GFP expression
was determined by flow cytometry in different
B cell types of a PromGFP transgenic mouse (line
3284-4; green area) and control littermate (black
line).
(B) Enhancer activity of the hypersensitive region
(HSR) in Pax5 intron 5. The transgene PromGFP-
ABC additionally contained a 4.7 kb DNA fragment
encompassing the intronic HS-A, HS-B, and HS-C
sites. The indicated hematopoietic cells types of
a PromGFP-ABC transgenic mouse line (3135-2)
were analyzed for GFP expression. See Experi-
mental Procedures for FACS definition of the
different cell types.
correlated with the presence of H3K9ac
and absence of H3K27me3, indicating
that the chromatin at these enhancer sites
is normally activated in the absence of
E2A and EBF1 (Figure 5C). In contrast,
the entire Pax5 promoter region (including
the existing HS-8) exhibited an inactive
histone modification pattern (H3K9ac
H3K27me3+) in Tcfe2a/ and Ebf1/
progenitors, demonstrating that the
promoter domain of Pax5 is silenced by
repressive chromatin in these cells
(Figure 5C). Together, these data demon-
strate that EBF1 is crucially required for
the remodeling and activation of chro-
matin in the Pax5 promoter region.
EBF1 has been implicated in the epige-
netic regulation of the Cd79a gene by
inducing DNA demethylation at the
Cd79a promoter in B lymphoid progeni-
tors (Maier et al., 2004). To investigate
the role of DNA demethylation in Pax5
locus activation, we determined the methylation state of
individual CpG dinucleotides at different Pax5 HS sites in
FACS-sorted MPPs, CLPs, pro-B cells, pre-B cells, and granulo-
cytes (Gran) of the bone marrow (Figure S11). DNA isolated from
these sorted cells, thymocytes (Thy), mouse embryo fibroblasts
(MEFs), and embryonic stem cells (ESCs) was subjected to
bisulfite treatment, which converts unmethylated cytosine to
uracil while leaving 5-methylcytosine unchanged. PCR products
of bisulfite-modified DNA were directly sequenced (Walter et al.,
2008), and the cytosine signal intensity at specific CpG dinucle-
otides was quantified, as shown for HS-A in Figure S12. This
analysis demonstrated that individual CpG dinucleotides located
within HS-2, HS-3, HS-A, and HS-B and adjacent to HS-7 were
largely unmethylated in all hematopoietic cell types including
MPPs and CLPs (Figure 5D). Only CpG dinucleotides flankingImmunity 30, 508–520, April 17, 2009 ª2009 Elsevier Inc. 513
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Figure 5. Stepwise Epigenetic Activation of the Pax5 Enhancer and Promoter Regions
(A and B) DNase I hypersensitivity mapping of the Pax5 promoter region (A) and intron 5 (B) with in vitro cultured Tcfe2a/and Ebf1/ progenitors or Pax5/
pro-B cells as described in Figures 3A and 3B.
(C) ChIP analysis. In vitro cultured Tcfe2a/ and Ebf1/ progenitors or Pax5/ and wild-type (WT) pro-B cells were used for ChIP analysis with H3K9ac and
H3K27me3 antibodies. Input and precipitated DNA were quantified by real-time PCR with primers amplifying the indicated HS sites, and the amount of precip-
itated DNA is shown as percentage relative to input DNA. The expressed Myc and silent Hoxa10 genes served as positive and negative controls, respectively.
The amplicon positions and results for all HS sites are shown in Figure 6A. Standard deviations of duplicate PCR measurements were determined for each ChIP
experiment. One of at least two ChIP experiments, which were performed with the same antibody, is shown for each cell type.
(D) DNA methylation analysis by bisulfite sequencing. The methylation state of individual CpG dinucleotides at different Pax5 HS sites was determined by
quantifying the C-to-U conversion after bisulfite treatment of DNA isolated from the indicated cell types (see also Figure S12). The extent of DNA methylation
is shown for individual CpG dinucleotides on a scale from 0 (complete C-to-U conversion; no CpG methylation) to 1 (no C-to-U conversion; complete CpG
methylation). Bars indicate CpG dinucleotides within (black) or flanking (white) the HS site. MPPs (LSKs), CLPs, pro-B cells, pre-B cells, and granulocytes
(Gran) were sorted from the bone marrow of wild-type mice as shown in Figure S11. Abbreviations: Thy, total thymocytes; ESC, embryonic stem cells; MEF,
mouse embryonic fibroblasts.HS-B revealed substantial DNA methylation in all hematopoietic
cells analyzed. Most CpG dinucleotides in the Pax5 promoter
region were also unmethylated in MEFs and ESCs, although
Pax5 enhancer sequences were efficiently methylated in both
cell types (Figure 5D). These data therefore indicated that DNA
demethylation of Pax5 enhancer sequences occurs either before
or at the onset of hematopoiesis in HSCs, whereas DNA methyl-
ation seems to play no role in the epigenetic regulation of the
Pax5 promoter region.
EBF1 Regulates the Pax5 Gene by Binding
to the Proximal Promoter Region
Because EBF1 and STAT5 were implicated in the regulation of
Pax5 by interacting with overlapping sites in the newly identified
HS-2 (Goetz et al., 2005; Hirokawa et al., 2003; O’Riordan and514 Immunity 30, 508–520, April 17, 2009 ª2009 Elsevier Inc.Grosschedl, 1999), we investigated the in vivo binding of EBF1,
STAT5, as well as E2A to this and all other Pax5 HS sites by
ChIP analysis in wild-type pro-B cells (Figures 6A and 6B).
STAT5 or E2A did not exhibit significant binding to any HS site
of the Pax5 locus, although STAT5 and E2A efficiently interacted
with the control Cish (STAT5 target) or Cd79a (E2A and EBF1
target) promoter, respectively (Figure 6B). In contrast, EBF1
bound efficiently to HS-7 and weakly to HS-6, but showed no
significant interaction with other HS sites including HS-2
(Figure 6B). Consistent with this result, a palindromic sequence
with a strong homology to the EBF1 consensus recognition
sequence (Travis et al., 1993) was present in HS-7, whereas
putative EBF1-binding sites with less homology were found in
HS-1 and HS-6 in addition to the previously identified site in
HS-2 (Figure 6C; O’Riordan and Grosschedl, 1999).
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Figure 6. In Vivo Binding of EBF1 to HS-7
(A) Location of the amplicons used for ChIP analysis.
(B) Binding of E2A, EBF1, and STAT5 to Pax5 HS sites.
Wild-type pro-B cells were used for ChIP analysis with E2A,
EBF1, and STAT5 antibodies or control IgG to detect
transcription factor binding to Pax5 HS sites and control
promoters of Cd79a (EBF/E2A target) andCish (STAT5 target).
Input and precipitated DNA was quantified by real-time PCR
with primers amplifying the indicated HS sites as described
in the legend of Figure 5. One of at least two ChIP experiments,
which were performed with the same antibody, is shown
together with the standard deviation of duplicate PCR
measurements.
(C) EBF-binding sites. Homologies of potential EBF1-binding
sites (identified by the TRANSFAC Professional 11.3 program)
with the EBF1 consensus recognition sequence (Travis et al.,
1993) are shown in red, and identical nucleotides of the mutant
(M) HS-7 sequence are indicated by a line.
(D) Identification of a high-affinity EBF1-binding site in HS-7.
A double-stranded oligonucleotide containing the EBF1
recognition sequence of HS-7 was used as a probe for EMSA
with a nuclear extract of WT pro-B cells. Double-stranded
oligonucleotides containing putative EBF1-binding sites
(shown in [C]) were analyzed at 20- or 100-fold molar excess
for competition of EBF1 binding. Addition of an EBF1 antibody
(aEBF1) prevented EBF1 binding.
(E) In vivo binding of EBF1 to HS-7. DMS footprinting was per-
formed with EBF1-expressing wild-type (1) and Pax5/ (3)
pro-B cells and EBF1-negative Tcfe2a/ progenitor cells
(2). DMS-modified and piperidine-cleaved DNA was amplified
by ligation-mediated PCR (LM-PCR) with primers specific for
HS-7. The G sequencing ladder of naked DNA (4) is shown
together with the EBF1 recognition sequence. Open circles
indicate the three G residues, which are protected by EBF1
binding.
(F) In vivo DNase I footprinting. Sorted CD19+ bone marrow B
lymphocytes (1), in vitro cultured Rag2/ pro-B cells (2), and
EBF1-nonexpressing Tcfe2a/ progenitor cells (3) were
permeabilized with the detergent NP-40 and digested with
DNase I. The cleaved DNA was amplified by LM-PCR with
HS-7-specific primers. The G sequencing ladder of naked
DNA (4) is shown together with the EBF1 recognition sequence
and the extent of DNase I protection by EBF1.Electrophoretic mobility shift assays (EMSAs) with an oligonucle-
otide probe containing the EBF1 recognition sequence of HS-7
revealed efficient protein binding to this site with a pro-B cell
nuclear extract (Figure 6D). The protein interacting with the
HS-7 site was identified as EBF1, because an oligonucleotide
with a point mutation (HS-7M) in the consensus binding site
was unable to compete and addition of an EBF1 antibody abol-
ished binding. Titration experiments with unlabeled competitor
fragments demonstrated that the EBF1 recognition sequence
in HS-7 has a similarly high affinity as the functional EBF1-
binding site of theCd79a promoter (Hagman et al., 1991). A puta-
tive EBF1-binding site in HS-6 competed for EBF1 binding with
low efficiency, whereas no competition could be detected with
the putative recognition sequence in HS-1 and HS-2. Taken
together, these experiments show that EBF1 binds with high
affinity only to HS-7.
The binding of EBF1 to its recognition sequence in HS-7 was
further confirmed by in vivo DMS and DNase I footprint experi-ments. As shown in Figure 6E, EBF1 protected the three G
residues of its binding site in HS-7 from DMS methylation in
EBF1-expressing wild-type (lane 1) and Pax5/ (lane 3) pro-B
cells, but not in EBF1-negative Tcfe2a/ progenitor cells
(lane 2). Likewise, the DNase I protection experiment shown in
Figure 6F identified a large footprint centered over the EBF1-
binding site of HS-7 in DNase I-treated CD19+ bone marrow B
lymphocytes (lane 1) and Rag2/ pro-B cells (lane 2) in contrast
to EBF1-deficient Tcfe2a/ progenitor cells (lane 3). Together,
these data indicate that EBF1 regulates thePax5 gene by binding
to a high-affinity binding site in HS-7.
PU.1, IRF4, IRF8, and NF-kB Control the Activity
of the Pax5 Enhancer
To identify upstream regulators of the Pax5 enhancer, we first
determined the sequence conservation of the HS-B site and
found that it consists of five highly conserved sequence blocks
(Figure 7A). Putative binding sites for known transcription factorsImmunity 30, 508–520, April 17, 2009 ª2009 Elsevier Inc. 515
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Figure 7. Activation of thePax5 Enhancer by
PU.1, IRF4, IRF8, and NF-kB Proteins
(A) Sequence conservation. The DNA sequence of
HS site B is shown together with a sequence
conservation track, transcription factor-binding
sites, and the DMS footprinting pattern obtained
with splenic B cells ([B] and Figure S13). The upper
DNA stand of the EICE and IRF-binding site was
not footprinted.
(B) In vivo DMS footprinting of HS-B in MEFs (2),
thymocytes (3), splenic B cells (4), CD19+ bone
marrow B lymphocytes (5), and wild-type pro-B
cells (6). In vitro DMS-treated genomic DNA (1)
served as control. G residues exhibiting DMS
protection (open circle) or enhanced reactivity
(closed circles) are indicated to the right and on
the lower DNA strand in (A).
(C) ChIP analysis. Nonstimulated cells of the
mature B cell line WEHI-279 were used for ChIP
analysis with PU.1, IRF4, IRF8, p50, c-Rel, and
Myc antibodies or control IgG to detect transcrip-
tion factor binding to the HS sites A, B, and C.
Known protein-binding sites in the 30Ek (PU.1,
IRF4, and IRF8), iEk (c-Rel), and H-2Kb (p50)
enhancers and in intron 1 of the nucleophosmin-1
(Npm1) gene (Myc) served as positive controls.
The ChIP results for all HS sites of Pax5 are shown
in Figure S14. One of at least two ChIP experi-
ments, which were performed with the same
antibody, is shown together with the standard
deviation of duplicate PCR measurements.
(D and E) Transient transfection assays. Luciferase
reporter genes carrying wild-type (WT) or mutant
(M) HS-B sequences upstream of a minimal
b-globin promoter were transfected with the
control vector pRL-SV40 into the mouse B cell
line M12.4.1. After 48 hr, luciferase activities were
measured, normalized, and displayed relative to
the activity of the parental vector Luc-S. Triplicate
measurements of the firefly and renilla luciferase
activities were used to determine the standard
deviation of the firefly to renilla luciferase ratio by
using the Gaussian law of error propagation. One
of three transient transfection experiments is
shown. Luc-2kB contains two copies of the
NF-kB site from the iEk enhancer. Rev indicates
reverse orientation.
(F) Sequence alignment of wild-type (WT) and
mutant (M) binding sites with the consensus
(cons) recognition sequence of the respective
transcription factors (Chen and Ghosh, 1999;
Escalante et al., 2002; Fujii et al., 1999). Black lines
denote identical nucleotides between mutant and
WT sequences. The EICE and IRF-binding
sequences are inverted relative to the sequence
shown in (A).could be identified in four of these conserved sequences
(Figures 7A and 7F) because they contained a consensus
E-box, a NF-kB-binding site (Chen and Ghosh, 1999), an Ets-IRF
composite element (EICE) (Escalante et al., 2002), and an IRF
recognition sequence (Fujii et al., 1999). The 50 part of the
conserved element in the middle of HS-B exhibits some
homology with the NF-kB consensus motif and is thus referred
as NF-kB-like element. In vivo DMS footprinting revealed protein
binding to all conserved elements in B cells (Figure 7B and516 Immunity 30, 508–520, April 17, 2009 ª2009 Elsevier Inc.Figure S13, lanes 4–6), whereas no DMS footprints were
detected in MEFs (lane 2) and thymocytes (lane 3) consistent
with the absence of HS site B in these cells. A similar footprint
pattern was observed in splenic B cells (lane 4) and bone marrow
B lymphocytes (lane 5), which predominantly consist of imma-
ture and mature B cells. No protein binding to the NF-kB site
was, however, detected in pro-B cells (lane 6) in agreement
with the absence of NF-kB DNA-binding activity in pro-B cells
(E. Derudder, M. Schmidt-Supprian, and K. Rajewsky, personal
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to the NF-kB-like element. This footprint differed, however, from
the NF-kB protection pattern, indicating that a so-far-unidenti-
fied transcription factor interacts with this element.
To confirm these footprinting data, we performed ChIP
analysis with unstimulated cells of the mature B cell line
WEHI-279 (Figure 7C; Figure S14A) and with in vitro cultured
pro-B cells (Figure S14B) to screen all HS sites of the Pax5 locus
for binding of PU.1, IRF4, IRF8, NF-kB, and Myc. The Ets protein
PU.1 and the interferon regulatory factors IRF4 and IRF8 specif-
ically bound only to HS site B of Pax5 both in pro-B and mature
B cells. The NF-kB1 subunits p50 and c-Rel also interacted with
HS-B in mature B cells, whereas no binding was detected in
pro-B cells (Figure S14B), in which NF-kB DNA-binding activity
is very low or absent (E. Derudder, M. Schmidt-Supprian, and
K. Rajewsky, personal communication). We failed to detect
significant binding of the E-box binding proteins Myc, USF1,
USF2, and E2A to the HS-B element in pro-B and mature B cells
(Figures 6B and 7C; Figure S14; data not shown).
We next investigated the functional significance of the
different protein-binding sites in HS site B by transient transfec-
tion of luciferase reporter constructs in the mature B cell line
M12.4.1. The activity of a minimal b-globin promoter (Luc-S)
was induced 30- to 100-fold by insertion of the entire HS-B
sequence in forward (Luc-HSB) or reverse (Luc-HSB-rev) orien-
tation, confirming that the HS-B region functions as an enhancer
in mature B cells (Figures 7D and 7E). Although enhancer activity
was not affected by an E-box mutation (M1), it was reduced to
60% by mutation of the NF-kB (M2) or the NF-kB-like (M3)
element and was further decreased to 35% by double mutation
of these sequences (M2+3; Figures 7E and 7F). The strongest
effect on enhancer activity was observed by inactivation of the
PU.1- and IRF-binding sites (M4, M5) in the Ets-IRF composite
element (EICE) or by mutation of the downstream IRF recognition
sequence (M6). Importantly, combined mutation of all five
conserved elements (M1–M6) completely eliminated the activity
of the HS-B enhancer. In summary, these data demonstrate that
the transcription factors PU.1, IRF4, IRF8, and NF-kB all
contribute to the regulation of the Pax5 HS-B enhancer during
early and late B cell development.
DISCUSSION
The hierarchical relationship between transcription factors
important for B cell development has mainly been studied by
genetic analysis of gene-deficient mice, retroviral rescue exper-
iments, and gene expression profiling (Cobaleda et al., 2007b;
Nutt and Kee, 2007). However, these experiments do not distin-
guish between direct and indirect regulation of a transcription
factor gene by its upstream regulators. To mechanistically
understand the activation of important transcription factor
genes, the cis-regulatory elements together with their upstream
regulators have to be identified and the impact of individual regu-
lators on chromatin structure and developmental expression
needs to be determined. By using different experimental
approaches, we have now defined the B cell-specific regulatory
elements of Pax5 and identified upstream regulators that control
Pax5 expression by binding to these elements.We identified seven B cell-specific HS sites and one ubiqui-
tous HS site in the Pax5 promoter region, which was shown by
transgenic analysis to have only a low intrinsic activity at the
pre-B and immature B cell stages of B lymphopoiesis. In
contrast, we could demonstrate correct B cell-specific expres-
sion of two large Pax5-Gfp BAC transgenes and used deletion
analysis to identify a potent enhancer region in intron 5 of
Pax5. This enhancer region contains four HS sites (A-D), two of
which (HS-A and HS-B) are B cell specific and carry active chro-
matin marks in pro-B cells. A Gfp transgene under the control of
the Pax5 promoter and enhancer regions recapitulated the
B lymphoid expression pattern of the endogenous Pax5 gene,
indicating that it contains the regulatory elements for correct
transcriptional initiation in early B cell development and repres-
sion during plasma cell differentiation. This Gfp transgene was
subject to position-effect variegation, so we classified the
regulatory elements in intron 5 as an enhancer rather than a locus
control region (LCR).
Genetic evidence has placed Tcfe2a (E2A) and Ebf1 upstream
of Pax5 in the transcriptional hierarchy of B cell development
(Nutt and Kee, 2007). Although E2A is expressed in MPPs,
lymphoid progenitors, and all B lymphocytes (Kwon et al.,
2008), it did not bind to any regulatory element of the Pax5
gene in pro-B cells. This finding is consistent with the fact that
Tcfe2a (E2A) acts upstream of Ebf1 (Lin and Grosschedl, 1995)
and that Ebf1 is a direct target gene of E2A (Seet et al., 2004;
Smith et al., 2002). Hence, E2A seems to indirectly contribute
to the regulation of Pax5 by activating the expression of Ebf1.
In contrast, our ChIP and in vivo footprinting analyses unambig-
uously identified Pax5 as a target gene of EBF1. Previous
experiments suggested that EBF1 binds to an element in HS-2
(O’Riordan and Grosschedl, 1999). However, we were unable
to verify this result by ChIP and EMSA analysis, but instead iden-
tified one high-affinity EBF1-binding site in HS-7 upstream of
exon 1B. In vivo footprinting demonstrated that EBF1 fully
occupies this site in pro-B cells, strongly suggesting that EBF1
regulates the Pax5 gene by binding to HS-7.
An important finding of our study is the demonstration that the
Pax5 promoter region lacks seven of its eight HS sites and
carries the repressive histone modification H3K27me3 in
Ebf1/ progenitors. These results identified an important and
unique role of EBF1 in regulating chromatin remodeling of the
entire Pax5 promoter region. It is currently unknown how binding
of EBF1 to HS-7 promotes long-range chromatin reorganization,
but it is likely that EBF1 cooperates with other factors to recruit
histone-modifying and chromatin-remodeling activities to the
Pax5 promoter region. This is consistent with the fact that
EBF1 interacts with the histone acetyltransferases p300 and
CBP (Zhao et al., 2003) and is involved in nucleosomal
remodeling of the Cd79a promoter (Maier et al., 2004). Hence,
the EBF1-dependent chromatin opening contributes to Pax5
activation by facilitating the interaction of the promoter domain
with the intronic enhancer region, which is activated prior to
EBF1 expression.
The repressive histone mark H3K27me3 is generated by the
Polycomb repressive complex 2 (PRC2) and is found at the
Pax5 promoter region in Pax5-nonexpressing MEFs (Mikkelsen
et al., 2008) and T cells (Wang et al., 2008). Moreover, ESCs
contain bivalent chromatin characterized by the coexistence ofImmunity 30, 508–520, April 17, 2009 ª2009 Elsevier Inc. 517
Immunity
B Cell-Specific Regulation of Pax5repressive H3K27me3 and active H3K4me3 modifications at the
Pax5 promoter region, which seems to be transcriptionally
poised for subsequent Pax5 activation in neural progenitors
during later embryogenesis (Bernstein et al., 2006; Mikkelsen
et al., 2008). We could not detect significant CpG methylation
at thePax5 promoter region in all cell types analyzed. Our histone
modification and DNA methylation data thus suggest the
following model for the epigenetic regulation of Pax5
(Figure S15). The Pax5 promoter region is repressed by Poly-
comb group proteins in ESCs and other non-B cells. This repres-
sion is overcome only at the onset of B cell development by the
expression of EBF1. In contrast, the Pax5 enhancer is kept silent
by DNA methylation in ESCs and MEFs, is only demethylated
before or at the onset of hematopoiesis, and is organized into
accessible chromatin in Ebf1/ lymphoid progenitors and at
subsequent B cell developmental stages. The Pax5 locus there-
fore undergoes stepwise epigenetic activation during develop-
ment as shown by the fact that its enhancer is already activated
in early hematopoietic progenitors, whereas the promoter region
becomes active only at the onset of B cell development.
Further insight into the sequential activation of Pax5 was
provided by identification of the transcription factors PU.1,
IRF4, IRF8, and NF-kB that interact with the HS-B site of the
Pax5 enhancer and regulate its activity in B cells. Interestingly,
the four transcription factors are sequentially expressed during
the differentiation of HSCs to mature B cells. The Ets transcrip-
tion factor PU.1 is expressed already in HSCs (Nutt et al.,
2005), where it is required for the development of multiple hema-
topoietic lineages including the differentiation of lymphoid
progenitors (Scott et al., 1994). Hence, PU.1 could already
bind to HS-B in multipotent hematopoietic progenitors, thereby
contributing to the early activation of the Pax5 enhancer
(Figure S15). PU.1 binding to the Ets-IRF composite element in
HS-B may be assisted by low amounts of IRF4 or IRF8 in these
early progenitors. Interestingly, Irf4 and Irf8 are direct Pax5
target genes, which are strongly upregulated at B cell commit-
ment (Schebesta et al., 2007). Hence, IRF4 and IRF8 may consti-
tute an indirect feedback loop, by which Pax5 regulates its own
enhancer activity (Figure S15). Finally, the inducible transcription
factor NF-kB is expressed in immature and mature B cells, where
its activity likely regulates the HS-B enhancer in response to
BCR, BAFF-R, or CD40 signaling (Sen, 2006).
The discovery of the Pax5 enhancer also contributes to our
understanding of the role of PAX5 cis-regulatory elements in
chromosomal translocations that are involved in the develop-
ment of B cell precursor acute lymphoblastic leukemia
(BCP-ALL) in human pediatric patients. In BCP-ALL, PAX5
participates in specific translocations that generate novel tran-
scription factors by fusing the N-terminal DNA-binding domain
of PAX5 to C-terminal sequences of different transcription
factors (FOXP1, ZNF521, PML, DACH1, and BRD1), kinases
(HIPK1 and JAK2), and structural proteins (POM121 and ELN)
(reviewed by Nebral et al., 2009). The breakpoints of these trans-
locations occur in PAX5 introns 5, 6, or 7 (Nebral et al., 2009) and
thus seem to be located downstream of the enhancer, which
leaves the regulatory elements of the PAX5 gene intact for B
cell-specific activation of the translocation alleles in BCP-ALL.
In summary, our study defined an enhancer and all B cell regu-
latory elements of Pax5, described the temporal sequence of518 Immunity 30, 508–520, April 17, 2009 ª2009 Elsevier Inc.epigenetic regulation at the Pax5 promoter and enhancer
regions, uncovered an important role of EBF1 in inducing chro-
matin accessibility of the Pax5 promoter region, and identified
PU.1, IRF4, IRF8, and NF-kB as critical regulators of the Pax5
HS-B enhancer in lymphoid progenitors and B cells.
EXPERIMENTAL PROCEDURES
Detailed methods can be found in the Supplemental Data available online.
Mice
Vav-cre Tcfe2afl/fl, Ebf1+/, and Pax5+/ mice were previously described
(Kwon et al., 2008; Lin and Grosschedl, 1995; Nutt et al., 1997). All animal
experiments were carried out according to valid project licenses, which
were approved and regularly controlled by the Austrian Veterinary Authorities.
Transgenes
BAC1 and BAC2 were generated by insertion of a Gfp reporter gene into Pax5
exon 2 of the mouse BAC clones 301J10 and 187L23 (Research Genomics)
and deletions were introduced by BAC recombineering. PromGFP and
PromGFP-ABC(D) were constructed via standard cloning procedures.
FACS Analysis and Sorting
Different hematopoietic cell types were analyzed by flow cytometry of the bone
marrow (MPPs to immature B cells, plasma cells, and non-B cells) and lymph
nodes (mature B cells): MPPs (LSKs; LinIL-7RaSca1hic-Kithi), CLPs
(LinIL-7Ra+Sca1loc-Kitlo), pro-B cells (CD19+c-Kit+), pre-B cells
(CD19+CD25+IgM), immature B cells (B220+CD19+IgMhiIgD), mature B cells
(CD93CD19+IgMloIgDhi), plasma cells (CD28+CD138hiLin [CD4CD8aF4/
80CD21]), and non-B cells (CD19B220).
DNase I Hypersensitivity Mapping
The protocol used for DNase I hypersensitivity mapping was previously
described (Tagoh et al., 2006). In brief, up to 108 cells were lyzed in DNase I
buffer (300 mM sucrose, 10 mM Tris-HCl [pH 7.5], 15 mM NaCl, 60 mM KCl,
5 mM MgCl2, 0.1 mM EGTA, 0.15 mM spermine, 0.5 mM spermidine) supple-
mented with 0.1% (w/v) NP-40 and Complete protease inhibitors (Roche).
Nuclei were isolated by centrifugation, resuspended in DNase I buffer, and
treated with increasing amounts of DNase I for 15 min followed by proteinase
K digestion and DNA isolation. The DNA was digested with the appropriate
restriction enzyme, separated by agarose gel electrophoresis, and analyzed
by southern blotting with radiolabeled DNA probes.
In Vitro Culture of Lymphoid Progenitors
Wild-type, Pax5/, Rag2/, and Pax5/ Rag2/ pro-B cells were cultured
as described (Nutt et al., 1997). Tcfe2a/ progenitors were generated by
in vitro culturing of sorted Lin bone marrow cells from Vav-cre Tcfe2afl/fl
and Ebf1/ mice as described (Kwon et al., 2008).
Antibodies
Rabbit polyclonal antibodies were raised against an N-terminal EBF1 polypep-
tide and the N-terminal E2A peptide PRRRAANGGLDTQPKKVRKV.
Antibodies against the histone modificiations H3K9Ac (07-352), H3K4me2
(07-030), and H3K4me3 (07-473) were purchased from Upstate Biotech-
nology. The H3K27me3 and STAT5a/b antibodies were kindly provided by
T. Jenuwein and T. Decker. The PU.1 antibody (G148-74) was obtained from
BD Biosciences and the following antibodies from Santa Cruz: p50
(sc-1190), c-Rel (sc-71), Myc (sc-764), IRF4 (sc-6059), IRF8 (sc-6058).
ChIP and ChIP-chip Analyses
ChIP analyses were performed as described (Schebesta et al., 2007). The
precipitated DNA was quantified by real-time PCR with a MyiQ instrument
(Bio-Rad). ChIP-chip experiments were carried out as described (Schebesta
et al., 2007). In brief, input DNA and DNA precipitated with histone tail modifi-
cation-specific antibodies were amplified, labeled, and hybridized to a 50-mer
oligonucleotide tiling array containing the Pax5 locus at 100 bp resolution
(produced by NimbleGen Systems).
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CpG methylation was analyzed by bisulfite sequencing as described (Walter
et al., 2008). In brief, genomic DNA was subjected to sodium bisulfite treatment
and purification via the EZ DNA Methylation Kit (Zymo Research). Purified DNA
was amplified by PCR with specific primers. DNA fragments were gel purified
and directly sequenced. The band intensities corresponding to T and C were
quantified with the PharosFX Plus system (BioRad) and Quantity One software.
The level of CpG methylation was determined as the ratio of intensity (C)/
[intensity (T) + intensity (C)].
Electrophoretic Mobility Shift Assays
Nuclear extracts of wild-type pro-B cells were generated, and EMSA analysis
was performed as described (Adams et al., 1992). In brief, labeled double-
stranded oligonucleotides (2 fmoles) were incubated with 1 mg of pro-B cell
nuclear extracts in binding buffer (20 mM HEPES [pH 7.9], 70 mM KCl,
2.5 mM MgCl2, 4% Ficoll, 100 mg/ml BSA, 0.1% (w/v) NP-40, 1 mM DTT,
0.05 mg/ml poly[d(I-C)]) for 30 min on ice. Protein-DNA complexes were sepa-
rated on a 6% polyacrylamide gel in 13 TGE buffer (25 mM Tris, 190 mM
glycine, 1 mM EDTA [pH 8.5]) followed by gel fixation and autoradiography.
In Vivo Footprint Analysis
In vivo DMS footprinting and ligation-mediated PCR amplification were per-
formed exactly as described (Tagoh et al., 2006). For in vivo DNase I footprint
analysis, cells were washed and resuspended at 108 cells per ml in buffer A
(11 mM KPO4 [pH 7.4], 108 mM KCl, 22 mM NaCl, 5 mM MgCl2, 1 mM
CaCl2, 1 mM DTT). Subsequently, 100 ml of this cell suspension was incubated
with 4 ml 10% NP40 and 100 ml of DNase I (at increasing concentrations from
20 to 150 U/ml) for 6 min at room temperature. The reaction was stopped by
proteinase K digestion followed by DNA preparation. The DNase I footprint
was detected by ligation-mediated PCR amplification as described (Tagoh
et al., 2006).
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